

Harris A Gelbard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/45906/publications.pdf>

Version: 2024-02-01

119
papers

6,980
citations

47006

47
h-index

62596

80
g-index

126
all docs

126
docs citations

126
times ranked

8242
citing authors

#	ARTICLE	IF	CITATIONS
1	Elucidating the neuropathophysiology of COVID-19 using quantum dot biomimetics of SARS-CoV-2. , 2022, , .		1
2	Clinical characteristics and outcomes after new-onset seizure among Zambian children with HIV during the antiretroviral therapy era. <i>Epilepsia Open</i> , 2022, 7, 315-324.	2.4	5
3	URMC-099 prophylaxis prevents hippocampal vascular vulnerability and synaptic damage in an orthopedic model of delirium superimposed on dementia. <i>FASEB Journal</i> , 2022, 36, e22343.	0.5	5
4	Quantum Dots for Improved Single-Molecule Localization Microscopy. <i>Journal of Physical Chemistry B</i> , 2021, 125, 2566-2576.	2.6	12
5	The Sez6 Family Inhibits Complement by Facilitating Factor I Cleavage of C3b and Accelerating the Decay of C3 Convertases. <i>Frontiers in Immunology</i> , 2021, 12, 607641.	4.8	18
6	Matters of size: Roles of hyaluronan in CNS aging and disease. <i>Ageing Research Reviews</i> , 2021, 72, 101485.	10.9	15
7	The Cell Culture Environment Regulates the Transcription Factor MafB in BV-2 Microglia. <i>Matters</i> , 2021, 2021, .	1.0	1
8	The darker side of varicella zoster infection. <i>Neurology</i> , 2020, 94, 193-194.	1.1	4
9	Survival and Motor Phenotypes in FVB C9-500 ALS/FTD BAC Transgenic Mice Reproduced by Multiple Labs. <i>Neuron</i> , 2020, 108, 784-796.e3.	8.1	22
10	Evaluating the impact of antiretroviral and antiseizure medication interactions on treatment effectiveness among outpatient clinic attendees with HIV in Zambia. <i>Epilepsia</i> , 2020, 61, 2705-2711.	5.1	1
11	This Is Your Brain on (Low) Glucose. <i>Trends in Neurosciences</i> , 2020, 43, 933-935.	8.6	1
12	Complement-dependent synapse loss and microgliosis in a mouse model of multiple sclerosis. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 739-750.	4.1	77
13	Neurovascular and immune mechanisms that regulate postoperative delirium superimposed on dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 734-749.	0.8	73
14	The broad spectrum mixed-lineage kinase 3 inhibitor URMC-099 prevents acute microgliosis and cognitive decline in a mouse model of perioperative neurocognitive disorders. <i>Journal of Neuroinflammation</i> , 2019, 16, 193.	7.2	25
15	The second generation mixed lineage kinase-3 (MLK3) inhibitor CLFB-1134 protects against neurotoxin-induced nigral dopaminergic neuron loss. <i>Experimental Neurology</i> , 2019, 318, 157-164.	4.1	7
16	Broad Spectrum Mixed Lineage Kinase Type 3 Inhibition and HIV-1 Persistence in Macrophages. <i>Journal of NeuroImmune Pharmacology</i> , 2019, 14, 44-51.	4.1	6
17	HIV Tat causes synapse loss in a mouse model of HIV-associated neurocognitive disorder that is independent of the classical complement cascade component C1q. <i>Glia</i> , 2018, 66, 2563-2574.	4.9	13
18	URMC-099 facilitates amyloid- β clearance in a murine model of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2018, 15, 137.	7.2	36

#	ARTICLE	IF	CITATIONS
19	Modulating cellular autophagy for controlled antiretroviral drug release. <i>Nanomedicine</i> , 2018, 13, 2139-2154.	3.3	9
20	The Mixed-Lineage Kinase Inhibitor URM-099 Protects Hippocampal Synapses in Experimental Autoimmune Encephalomyelitis. <i>ENeuro</i> , 2018, 5, ENEURO.0245-18.2018.	1.9	15
21	HAND Adjunctive Therapies: Reversing Neuronal Injury. , 2018, , 599-604.		0
22	Neuroimmune Pharmacology, 2nd Edition – A Perspective. <i>Journal of Neuroimmune Pharmacology</i> , 2017, 12, 211-212.	4.1	1
23	Mixed-lineage kinase 3 pharmacological inhibition attenuates murine nonalcoholic steatohepatitis. <i>JCI Insight</i> , 2017, 2, .	5.0	30
24	Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs. <i>Journal of Clinical Investigation</i> , 2017, 127, 857-873.	8.2	44
25	Capillary extraction by detecting polarity in circular profiles. <i>IET Image Processing</i> , 2016, 10, 339-348.	2.5	0
26	The mixed-lineage kinase 3 inhibitor URM-099 facilitates microglial amyloid- β degradation. <i>Journal of Neuroinflammation</i> , 2016, 13, 184.	7.2	22
27	Platelet-Activating Factor Receptors Mediate Excitatory Postsynaptic Hippocampal Injury in Experimental Autoimmune Encephalomyelitis. <i>Journal of Neuroscience</i> , 2016, 36, 1336-1346.	3.6	38
28	The mixed lineage kinase-3 inhibitor URM-099 improves therapeutic outcomes for long-acting antiretroviral therapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 109-122.	3.3	27
29	Leucine-Rich Repeat Kinase 2 Modulates Neuroinflammation and Neurotoxicity in Models of Human Immunodeficiency Virus 1-Associated Neurocognitive Disorders. <i>Journal of Neuroscience</i> , 2015, 35, 5271-5283.	3.6	50
30	Platelet Activating Factor Enhances Synaptic Vesicle Exocytosis Via PKC, Elevated Intracellular Calcium, and Modulation of Synapsin 1 Dynamics and Phosphorylation. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 505.	3.7	20
31	HAND Adjunctive Therapies: Reversing Neuronal Injury. , 2015, , 1-6.		0
32	Pharmacologic Inhibition of MLK3 Kinase Activity Blocks the In Vitro Migratory Capacity of Breast Cancer Cells but Has No Effect on Breast Cancer Brain Metastasis in a Mouse Xenograft Model. <i>PLoS ONE</i> , 2014, 9, e108487.	2.5	9
33	Associations between brain microstructures, metabolites, and cognitive deficits during chronic HIV-1 infection of humanized mice. <i>Molecular Neurodegeneration</i> , 2014, 9, 58.	10.8	52
34	Allotransplanted DRG neurons or Schwann cells affect functional recovery in a rodent model of sciatic nerve injury. <i>Neurological Research</i> , 2014, 36, 1020-1027.	1.3	6
35	Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 585-590.	3.8	15
36	Endosomal Trafficking of Nanoformulated Antiretroviral Therapy Facilitates Drug Particle Carriage and HIV Clearance. <i>Journal of Virology</i> , 2014, 88, 9504-9513.	3.4	48

#	ARTICLE	IF	CITATIONS
37	MLK3 regulates fMLP-stimulated neutrophil motility. <i>Molecular Immunology</i> , 2014, 58, 214-222.	2.2	21
38	Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients. <i>Journal of NeuroVirology</i> , 2013, 19, 254-260.	2.1	14
39	Discovery, Synthesis, and Characterization of an Orally Bioavailable, Brain Penetrant Inhibitor of Mixed Lineage Kinase 3. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 8032-8048.	6.4	69
40	Directional histogram ratio at random probes: A local thresholding criterion for capillary images. <i>Pattern Recognition</i> , 2013, 46, 1933-1948.	8.1	6
41	The New Small-Molecule Mixed-Lineage Kinase 3 Inhibitor URM-099 Is Neuroprotective and Anti-Inflammatory in Models of Human Immunodeficiency Virus-Associated Neurocognitive Disorders. <i>Journal of Neuroscience</i> , 2013, 33, 9998-10010.	3.6	65
42	Ultrastructure of microglia-synapse interactions in the HIV-1 Tat-injected murine central nervous system. <i>Communicative and Integrative Biology</i> , 2013, 6, e27670.	1.4	27
43	Lipids and cognition make good bedfellows for neuroAIDS. <i>Neurology</i> , 2013, 81, 1480-1481.	1.1	2
44	Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. <i>Aids</i> , 2012, 26, 2135-2144.	2.2	121
45	LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein. <i>Journal of Neuroinflammation</i> , 2012, 9, 261.	7.2	77
46	Near-field Quantification of Complement Receptor 1 (CR1/CD35) Protein Clustering in Human Erythrocytes. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 539-543.	4.1	10
47	Allotransplanted Neurons Used to Repair Peripheral Nerve Injury Do Not Elicit Overt Immunogenicity. <i>PLoS ONE</i> , 2012, 7, e31675.	2.5	19
48	Mitochondrial membrane potential probes and the proton gradient: a practical usage guide. <i>BioTechniques</i> , 2011, 50, 98-115.	1.8	924
49	HIV-1 Tat-Induced Microgliosis and Synaptic Damage via Interactions between Peripheral and Central Myeloid Cells. <i>PLoS ONE</i> , 2011, 6, e23915.	2.5	63
50	Two-Photon NADH Imaging Exposes Boundaries of Oxygen Diffusion in Cortical Vascular Supply Regions. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 68-81.	4.3	141
51	Loss of Neuronal Integrity during Progressive HIV-1 Infection of Humanized Mice. <i>Journal of Neuroscience</i> , 2011, 31, 3148-3157.	3.6	110
52	A Thin-skull Window Technique for Chronic Two-photon & In vivo & Imaging of Murine Microglia in Models of Neuroinflammation. <i>Journal of Visualized Experiments</i> , 2010, , .	0.3	56
53	Rebuilding Synaptic Architecture in HIV-1 Associated Neurocognitive Disease: A Therapeutic Strategy Based on Modulation of Mixed Lineage Kinase. <i>Neurotherapeutics</i> , 2010, 7, 392-398.	4.4	11
54	Human Immunodeficiency Virus-1 Tat Activates Calpain Proteases via the Ryanodine Receptor to Enhance Surface Dopamine Transporter Levels and Increase Transporter-Specific Uptake and Vmax. <i>Journal of Neuroscience</i> , 2010, 30, 14153-14164.	3.6	54

#	ARTICLE	IF	CITATIONS
55	Neuroprotective Activities of CEP-1347 in Models of NeuroAIDS. <i>Journal of Immunology</i> , 2010, 184, 746-756.	0.8	47
56	Ablation of mixed lineage kinase 3 (Mlk3) does not inhibit ototoxicity induced by acoustic trauma or aminoglycoside exposure. <i>Hearing Research</i> , 2010, 270, 21-27.	2.0	8
57	Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders. <i>Journal of Neuroimmunology</i> , 2009, 213, 47-59.	2.3	24
58	Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. <i>Journal of NeuroVirology</i> , 2009, 15, 176-186.	2.1	90
59	Effects of Minocycline and Valproic Acid Coadministration on Atazanavir Plasma Concentrations in Human Immunodeficiency Virus-Infected Adults Receiving Atazanavir-Ritonavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3035-3039.	3.2	18
60	HIV-1 Tat Activates Neuronal Ryanodine Receptors with Rapid Induction of the Unfolded Protein Response and Mitochondrial Hyperpolarization. <i>PLoS ONE</i> , 2008, 3, e3731.	2.5	96
61	Functional Synergy between CD40 Ligand and HIV-1 Tat Contributes to Inflammation: Implications in HIV Type 1 Dementia. <i>Journal of Immunology</i> , 2007, 178, 3226-3236.	0.8	79
62	HIV-1 Trans Activator of Transcription Protein Elicits Mitochondrial Hyperpolarization and Respiratory Deficit, with Dysregulation of Complex IV and Nicotinamide Adenine Dinucleotide Homeostasis in Cortical Neurons. <i>Journal of Immunology</i> , 2007, 178, 869-876.	0.8	78
63	Glycogen Synthase Kinase 3 Beta (GSK-3 β) as a Therapeutic Target in NeuroAIDS. <i>Journal of NeuroImmune Pharmacology</i> , 2007, 2, 93-96.	4.1	39
64	The Phospholipid Mediator Platelet-Activating Factor Mediates Striatal Synaptic Facilitation. <i>Journal of NeuroImmune Pharmacology</i> , 2007, 2, 194-201.	4.1	15
65	Human immunodeficiency virus-encoded Tat activates glycogen synthase kinase-3 β to antagonize nuclear factor- κ B survival pathway in neurons. <i>European Journal of Neuroscience</i> , 2006, 23, 2623-2634.	2.6	43
66	Protecting the Synapse: Evidence for a Rational Strategy to Treat HIV-1 Associated Neurologic Disease. <i>Journal of NeuroImmune Pharmacology</i> , 2006, 1, 20-31.	4.1	30
67	Inhibition of Mixed Lineage Kinase 3 Prevents HIV-1 Tat-Mediated Neurotoxicity and Monocyte Activation. <i>Journal of Immunology</i> , 2006, 177, 702-711.	0.8	50
68	Adjunctive therapies for HIV-1 associated neurologic disease. <i>Neurotoxicity Research</i> , 2005, 8, 161-166.	2.7	20
69	Neuroprotective Mechanisms of Lithium in Murine Human Immunodeficiency Virus-1 Encephalitis. <i>Journal of Neuroscience</i> , 2005, 25, 8375-8385.	3.6	72
70	HIV-1 Transactivator of Transcription Protein Induces Mitochondrial Hyperpolarization and Synaptic Stress Leading to Apoptosis. <i>Journal of Immunology</i> , 2005, 174, 4333-4344.	0.8	95
71	Synaptic activity becomes excitotoxic in neurons exposed to elevated levels of platelet-activating factor. <i>Journal of Clinical Investigation</i> , 2005, 115, 3185-3192.	8.2	72
72	Effects of Valproic Acid Coadministration on Plasma Efavirenz and Lopinavir Concentrations in Human Immunodeficiency Virus-Infected Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4328-4331.	3.2	59

#	ARTICLE	IF	CITATIONS
73	Immunohistochemical Assessment of Fractalkine, Inflammatory Cells, and Human Herpesvirus 7 in Human Salivary Glands. <i>Journal of Histochemistry and Cytochemistry</i> , 2004, 52, 671-681.	2.5	14
74	Productive infection of primary murine astrocytes, lymphocytes, and macrophages by human immunodeficiency virus type 1 in culture. <i>Journal of NeuroVirology</i> , 2004, 10, 400-408.	2.1	18
75	Neuroprotective strategies for HIV-1 associated dementia. <i>Neurotoxicity Research</i> , 2004, 6, 503-521.	2.7	29
76	Activation of adenosine A2A receptor protects sympathetic neurons against nerve growth factor withdrawal. <i>Journal of Neuroscience Research</i> , 2004, 77, 258-269.	2.9	17
77	Antioxidants are required during the early critical period, but not later, for neuronal survival. <i>Journal of Neuroscience Research</i> , 2004, 78, 485-492.	2.9	69
78	Effects of human immunodeficiency virus type 1 on astrocyte gene expression and function: Potential role in neuropathogenesis. <i>Journal of NeuroVirology</i> , 2004, 10, 25-32.	2.1	102
79	The Neuropathogenesis of HIV-1 Infection. , 2004, , 95-115.		8
80	Activated Protein C Prevents Neuronal Apoptosis via Protease Activated Receptors 1 and 3. <i>Neuron</i> , 2004, 41, 563-572.	8.1	243
81	Synapses and Sisyphus: life without paraplegin. <i>Journal of Clinical Investigation</i> , 2004, 113, 185-187.	8.2	7
82	Reduced expression of glutamate transporter EAAT2 and impaired glutamate transport in human primary astrocytes exposed to HIV-1 or gp120. <i>Virology</i> , 2003, 312, 60-73.	2.4	194
83	Neuroprotective Activities of Sodium Valproate in a Murine Model of Human Immunodeficiency Virus-1 Encephalitis. <i>Journal of Neuroscience</i> , 2003, 23, 9162-9170.	3.6	113
84	HIV-1 Tat-Mediated Activation of Glycogen Synthase Kinase-3 β Contributes to Tat-Mediated Neurotoxicity. <i>Journal of Neurochemistry</i> , 2002, 73, 578-586.	3.9	162
85	Tumor Necrosis Factor-Alpha in Normal and Diseased Brain: Conflicting Effects Via Intraneuronal Receptor Crosstalk?. <i>Journal of NeuroVirology</i> , 2002, 8, 611-624.	2.1	98
86	HIV-1-associated dementia: a basic science and clinical perspective. <i>Aids Reader</i> , 2002, 12, 358-68.	0.3	34
87	Functional Interplay Between Nuclear Factor- κ B and c-Jun Integrated by Coactivator p300 Determines the Survival of Nerve Growth Factor-Dependent PC12 Cells. <i>Journal of Neurochemistry</i> , 2001, 74, 527-539.	3.9	38
88	Neurotrophins prevent HIV Tat-induced neuronal apoptosis via a nuclear factor- κ B (NF- κ B)-dependent mechanism. <i>Journal of Neurochemistry</i> , 2001, 78, 874-889.	3.9	81
89	Activation of glycogen synthase kinase 3 beta (GSK-3 β) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. <i>European Journal of Neuroscience</i> , 2001, 13, 1913-1922.	2.6	85
90	Comparison of Cell Cycle Arrest, Transactivation, and Apoptosis Induced by the Simian Immunodeficiency Virus SIVagm and Human Immunodeficiency Virus Type 1 vpr Genes. <i>Journal of Virology</i> , 2001, 75, 3791-3801.	3.4	85

#	ARTICLE	IF	CITATIONS
91	Release of the neuronal glycoprotein ICAM-5 in serum after hypoxic-ischemic injury. <i>Annals of Neurology</i> , 2000, 48, 590-602.	5.3	24
92	Neuronal Fractalkine Expression in HIV-1 Encephalitis: Roles for Macrophage Recruitment and Neuroprotection in the Central Nervous System. <i>Journal of Immunology</i> , 2000, 164, 1333-1339.	0.8	186
93	Release of the neuronal glycoprotein ICAM-5 in serum after hypoxic-ischemic injury. <i>Annals of Neurology</i> , 2000, 48, 590-602.	5.3	1
94	Neuroprotective Strategies for HIV-1-Associated Neurologic Disease. <i>Annals of the New York Academy of Sciences</i> , 1999, 890, 312-313.	3.8	14
95	Proteasome blockers inhibit TNF- α release by lipopolysaccharide stimulated macrophages and microglia: implications for HIV-1 dementia. <i>Journal of Neuroimmunology</i> , 1999, 95, 55-64.	2.3	24
96	Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1-associated dementia. <i>Journal of Neuroimmunology</i> , 1999, 98, 185-200.	2.3	299
97	HIV-1-induced neuronal injury in the developing brain. <i>Journal of Leukocyte Biology</i> , 1999, 65, 453-457.	3.3	82
98	HIV-1 Infection of the CNS. , 1999, , 511-519.		0
99	Luciferase: a sensitive and quantitative probe for blood-brain barrier disruption. <i>Journal of Neuroscience Methods</i> , 1998, 83, 159-164.	2.5	6
100	Progressive accumbens degeneration after neonatal striatal 6-hydroxydopamine in rats. <i>Neuroscience Letters</i> , 1998, 247, 99-102.	2.1	6
101	Platelet-activating Factor Receptor Activation. <i>Journal of Biological Chemistry</i> , 1998, 273, 17660-17664.	3.4	114
102	HIV-1 Tat Induces Neuronal Death via Tumor Necrosis Factor- α and Activation of Non-N-methyl-d-aspartate Receptors by a NF- κ B-Independent Mechanism. <i>Journal of Biological Chemistry</i> , 1998, 273, 17852-17858.	3.4	171
103	Human Immunodeficiency Virus Type 1 Infection. <i>Frontiers in Neuroscience</i> , 1998, ,	0.0	0
104	Human immunodeficiency virus type 1 Tat protein induces death by apoptosis in primary human neuron cultures. <i>Journal of NeuroVirology</i> , 1997, 3, 168-173.	2.1	150
105	Apoptosis in development and disease of the nervous system: II. Apoptosis in childhood neurologic disease. <i>Pediatric Neurology</i> , 1997, 16, 93-97.	2.1	22
106	In Situ Trypan Blue Staining of Monolayer Cell Cultures for Permanent Fixation and Mounting. <i>BioTechniques</i> , 1997, 22, 1020-1024.	1.8	49
107	Simultaneous In Situ Detection of Apoptosis and Necrosis in Monolayer Cultures by TUNEL and Trypan Blue Staining. <i>BioTechniques</i> , 1997, 22, 1102-1106.	1.8	66
108	Tumor Necrosis Factor α Inhibits Glutamate Uptake by Primary Human Astrocytes. <i>Journal of Biological Chemistry</i> , 1996, 271, 15303-15306.	3.4	291

#	ARTICLE	IF	CITATIONS
109	Neuropathogenesis of AIDS. Trends in Molecular Medicine, 1996, 2, 16-23.	2.6	43
110	The regulation of quinolinic acid in human immunodeficiency virus-infected monocytes. Journal of NeuroVirology, 1996, 2, 111-117.	2.1	39
111	HIV-1-Derived Neurotoxic Factors: Effects on Human Neuronal Cultures. , 1995, , 61-71.		1
112	HIV-1 infection of the developing nervous system: central role of astrocytes in pathogenesis. Virus Research, 1994, 32, 253-267.	2.2	84
113	Developmental Differences in Acute Nigrostriatal and Mesocorticolimbic System Response to Haloperidol. Neuropsychopharmacology, 1993, 9, 147-156.	5.4	86
114	Neurotoxic Effects of Tumor Necrosis Factor Alpha in Primary Human Neuronal Cultures are Mediated by Activation of the Glutamate AMPA Receptor Subtype: Implications for AIDS Neuropathogenesis. Developmental Neuroscience, 1993, 15, 417-422.	2.0	165
115	Dopamine D1 autoreceptor function: possible expression in developing rat prefrontal cortex and striatum. Developmental Brain Research, 1991, 63, 229-235.	1.7	36
116	Dopamine D1 receptor development depends on endogenous dopamine. Developmental Brain Research, 1990, 56, 137-140.	1.7	50
117	Postnatal development of dopamine D1 and D2 receptor sites in rat striatum. Developmental Brain Research, 1989, 49, 123-130.	1.7	128
118	Characteristics of [3H]11 β , 25-(OH)2D3 binding to nuclear fractions from rat pituitary adenoma GH3 cells. Life Sciences, 1981, 29, 1051-1056.	4.3	4
119	Neuroimmunology and the Pathogenesis of HIV-1 Encephalitis in the HAART Era: Implications for Neuroprotective Treatment. , 0, , 137-149.		0